X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PFIZER - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PFIZER SANOFI INDIA/
PFIZER
 
P/E (TTM) x 38.3 34.2 112.0% View Chart
P/BV x 7.2 4.8 149.3% View Chart
Dividend Yield % 0.5 0.7 74.6%  

Financials

 SANOFI INDIA   PFIZER
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
PFIZER
Mar-18
SANOFI INDIA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs4,9452,365 209.1%   
Low Rs3,9011,625 240.1%   
Sales per share (Unadj.) Rs1,081.8430.3 251.4%  
Earnings per share (Unadj.) Rs141.678.7 179.9%  
Cash flow per share (Unadj.) Rs185.993.2 199.5%  
Dividends per share (Unadj.) Rs33.0020.00 165.0%  
Dividend yield (eoy) %0.71.0 74.4%  
Book value per share (Unadj.) Rs868.8586.5 148.1%  
Shares outstanding (eoy) m23.0345.75 50.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.14.6 88.2%   
Avg P/E ratio x31.225.3 123.3%  
P/CF ratio (eoy) x23.821.4 111.1%  
Price / Book Value ratio x5.13.4 149.7%  
Dividend payout %23.325.4 91.7%   
Avg Mkt Cap Rs m101,86291,271 111.6%   
No. of employees `0003.22.6 123.2%   
Total wages/salary Rs m3,6853,143 117.2%   
Avg. sales/employee Rs Th7,691.97,484.8 102.8%   
Avg. wages/employee Rs Th1,137.71,195.0 95.2%   
Avg. net profit/employee Rs Th1,006.51,369.1 73.5%   
INCOME DATA
Net Sales Rs m24,91419,685 126.6%  
Other income Rs m8071,143 70.6%   
Total revenues Rs m25,72120,828 123.5%   
Gross profit Rs m5,3725,003 107.4%  
Depreciation Rs m1,022663 154.3%   
Interest Rs m114 261.9%   
Profit before tax Rs m5,1465,479 93.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8861,878 100.4%   
Profit after tax Rs m3,2603,601 90.5%  
Gross profit margin %21.625.4 84.8%  
Effective tax rate %36.634.3 106.9%   
Net profit margin %13.118.3 71.5%  
BALANCE SHEET DATA
Current assets Rs m14,43224,167 59.7%   
Current liabilities Rs m6,0109,544 63.0%   
Net working cap to sales %33.874.3 45.5%  
Current ratio x2.42.5 94.8%  
Inventory Days Days6155 110.5%  
Debtors Days Days2829 99.2%  
Net fixed assets Rs m7,9919,514 84.0%   
Share capital Rs m230458 50.3%   
"Free" reserves Rs m19,77826,375 75.0%   
Net worth Rs m20,00826,832 74.6%   
Long term debt Rs m025 0.0%   
Total assets Rs m27,77036,900 75.3%  
Interest coverage x468.81,305.5 35.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.5 168.2%   
Return on assets %11.89.8 120.6%  
Return on equity %16.313.4 121.4%  
Return on capital %25.820.4 126.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,30622 28,151.8%   
Fx outflow Rs m5,2571,489 353.1%   
Net fx Rs m1,049-1,466 -71.5%   
CASH FLOW
From Operations Rs m4,3513,318 131.1%  
From Investments Rs m-787-2,383 33.0%  
From Financial Activity Rs m-1,884-1,104 170.7%  
Net Cashflow Rs m1,680-169 -997.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 63.9 94.5%  
Indian inst/Mut Fund % 14.4 7.5 192.0%  
FIIs % 14.6 4.9 298.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.7 44.3%  
Shareholders   15,184 85,207 17.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  FULFORD INDIA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 17, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - SHASUN PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS